Plain-English translation of NCT06182072 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called ProAgio to see if it can help treat advanced pancreatic cancer. ProAgio works by targeting blood vessels that feed cancer tumors. Researchers are studying whether this medication works better when combined with standard chemotherapy drugs, and whether adding an immunotherapy drug might help even more.
Pancreatic cancer is very difficult to treat, and current standard treatments don't work well enough for many patients. This trial exists to see if this new medication could be a better option by attacking cancer in a different way than existing treatments.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous (IV) infusions of the medication and/or chemotherapy drugs on specific days within each 4-week treatment cycle. You will have frequent blood tests and imaging scans every 2 months to check how you are responding to treatment. The study involves multiple visits to the clinic, and your participation will continue as long as the treatment is working and you are tolerating it well.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States